Cellular changes in eculizumab early responders with generalized myasthenia gravis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cellular changes in eculizumab early responders with generalized myasthenia gravis

Published:2021-10 Issue: Volume:231 Page:108830
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Li Yingkai,Yi John S.,Howard James F.,Chopra Manisha,Russo Melissa A.,Guptill Jeffrey T.

Funder

UCB Pharma

National Institute of Allergy and Infectious Diseases

National Institute of Neurological Disorders and Stroke

National Institutes of Health

National Institute of Mental Health

Myasthenia Gravis Foundation of America

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference30 articles.

1. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria;Rother;Nat. Biotechnol.,2007

2. Myasthenia gravis activities of daily living profile;Wolfe;Neurology,1999

3. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America;Jaretzki;Neurology,2000

4. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score;Sanders;Ann. N. Y. Acad. Sci.,2003

5. Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis;Li;J. Neuroimmunol.,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An angel or a devil? Current view on the role of CD8+ T cells in the pathogenesis of myasthenia gravis;Journal of Translational Medicine;2024-02-20

2. Peripheral memory B cells in multiple sclerosis vs. double negative B cells in neuromyelitis optica spectrum disorder: disease driving B cell subsets during CNS inflammation;Frontiers in Cellular Neuroscience;2024-02-07

3. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies;Nature Reviews Neurology;2024-01-08

4. The safety and efficacy profile of eculizumab in myasthenic crisis: a prospective small case series;Therapeutic Advances in Neurological Disorders;2024-01

5. Novel pathophysiological insights in autoimmune myasthenia gravis;Current Opinion in Neurology;2022-08-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3